Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study.


Journal

Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142

Informations de publication

Date de publication:
03 2020
Historique:
entrez: 1 5 2020
pubmed: 1 5 2020
medline: 21 5 2021
Statut: ppublish

Résumé

The burden of hepatocellular carcinoma (HCC) occurring in patients with alcoholic liver disease (ALD) is increasing at an alarming rate. The aims of this study were to compare the patient and tumor characteristics of HCC occurring in ALD-alone relative to and in addition to other chronic liver diseases. Patients diagnosed with HCC between 2000 and 2014 were identified at 5 US clinical centers. The patients were categorized as ALD-alone, ALD plus viral hepatitis, or a non-ALD etiology. Clinical and tumor characteristics among the 3 groups were compared, and survival probability was estimated by the Kaplan-Meier method. The frequency of noncirrhotic HCC was compared across the 3 groups. A total of 5,327 patients with HCC were analyzed. Six hundred seventy (12.6%) developed HCC due to underlying ALD. Ninety-one percent of ALD-related HCC arose in men, in contrast to non-ALD etiologies where men accounted for 70% of HCCs cases (P < 0.001). Patients with ALD-alone-related HCC were older at diagnosis and had tumors less likely to be detected as part of routine surveillance. The ALD-alone cohort was least likely to be within the Milan criteria and to undergo liver transplantation. Overall survival in the ALD-alone HCC cohort was lower than the other 2 groups (1.07 vs 1.31 vs 1.41 years, P < 0.001). HCC in the noncirrhotic ALD cohorts occurred in only 3.5% of the patients compared with 15.7% in patients with non-ALD etiologies (P < 0.001). HCC occurring in patients with ALD occurred mostly in older men and almost exclusively in a cirrhotic background. They present with advanced tumors, and their survival is lower than HCCs occurring in non-ALD.

Identifiants

pubmed: 32352723
doi: 10.14309/ctg.0000000000000139
pii: 01720094-202003000-00020
pmc: PMC7145044
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00139

Références

Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Clin Gastroenterol Hepatol. 2018 Aug;16(8):1356-1358
pubmed: 29199144
Gastroenterology. 2015 Nov;149(6):1471-1482.e5; quiz e17-8
pubmed: 26255044
Cancer Prev Res (Phila). 2012 Sep;5(9):1124-30
pubmed: 22846843
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
J Hepatol. 2019 Sep;71(3):523-533
pubmed: 31145929
J Natl Compr Canc Netw. 2019 Apr 1;17(4):322-329
pubmed: 30959469
Transplantation. 2019 Jan;103(1):131-139
pubmed: 30300285
Cancer. 2018 May 1;124(9):1964-1972
pubmed: 29589878
Am J Gastroenterol. 2018 Oct;113(10):1475-1483
pubmed: 29535416
J Hepatol. 2017 Aug 24;:
pubmed: 28844936
J Hepatol. 2019 Feb;70(2):284-293
pubmed: 30658729
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Hepatology. 2002 Nov;36(5):1206-13
pubmed: 12395331
Aliment Pharmacol Ther. 2016 Feb;43(3):385-99
pubmed: 26662476
Alcohol Clin Exp Res. 1994 Oct;18(5):1267-71
pubmed: 7847618
Liver Cancer. 2012 Nov;1(3-4):257-66
pubmed: 24159590
Hepatology. 2015 Dec;62(6):1723-30
pubmed: 26274335
Hepatology. 2019 Mar;69(3):1064-1074
pubmed: 30014489
Aliment Pharmacol Ther. 2019 Oct;50(7):809-821
pubmed: 31475372
Mutagenesis. 2008 Jan;23(1):51-6
pubmed: 17989147
J Hepatol. 2018 Dec;69(6):1274-1283
pubmed: 30092234
Clin Gastroenterol Hepatol. 2016 Jan;14(1):124-31.e1
pubmed: 26196445
Lancet. 2018 Sep 22;392(10152):1015-1035
pubmed: 30146330
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029

Auteurs

Andrew deLemos (A)

Department of Medicine, Atrium Health, Charlotte, North Carolina, USA.

Milin Patel (M)

Department of Medicine, Atrium Health, Charlotte, North Carolina, USA.

Samer Gawrieh (S)

Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Heather Burney (H)

Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Lara Dakhoul (L)

Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Ethan Miller (E)

Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, Houston, Texas, USA.

Andrew Scanga (A)

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

Carla Kettler (C)

Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Hao Liu (H)

Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Patrick Roche (P)

Department of Medicine, Atrium Health, Charlotte, North Carolina, USA.

Julia Wattacheril (J)

Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.

Naga Chalasani (N)

Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH